10 years ago

Kesios Therapeutics Raises £19 Million to Develop Novel Cancer Treatments

  • Kesios Therapeutics, a London-based company developing novel therapeutics for the treatment of multiple myeloma and other cancers, has secured £19 million in Series A funding

  • The round was led by Imperial Innovations Group plc, SV Life Sciences, and Abingworth

  • Kesios is developing drug candidates that exploit a novel target within the nuclear factor kappa B (NF-κB) pathway to promote cancer cell survival in certain white blood cells of patients with multiple myeloma and other malignancies

  • Their lead drug candidate, KES-0001, is about to enter clinical studies as a potential treatment for multiple myeloma.

      • ProblemHealthcare

      "Multiple myeloma is a blood cancer that affects plasma cells, which are a type of white blood cell. It's a serious disease with limited treatment options, and patients often experience relapses. The existing treatments can have severe side effects. "

      Solution

      "Kesios Therapeutics is developing new drugs that target the NF-κB pathway. This pathway is important for cancer cell survival in certain white blood cells. By targeting this pathway, Kesios hopes to develop drugs that are more effective and have fewer side effects than existing treatments."

      Covered on